NCT00292591

Brief Summary

The purpose of this study is to determine the effectiveness of vitamin D supplementation during pregnancy starting at the beginning of the second trimester. Mothers will be randomized to one of three vitamin D dosing groups: 400, 2,000 or 4,000 international units per day. It is hypothesized that the highest dosing regimen will result in a better vitamin D status of women regardless of their ethnicity or race.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
501

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Jan 2004

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2004

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

February 15, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 16, 2006

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2010

Completed
6.6 years until next milestone

Results Posted

Study results publicly available

August 9, 2016

Completed
Last Updated

September 19, 2016

Status Verified

August 1, 2016

Enrollment Period

6 years

First QC Date

February 15, 2006

Results QC Date

June 28, 2016

Last Update Submit

August 9, 2016

Conditions

Keywords

vitamin Dcholecalciferolpregnancybone mineral density

Outcome Measures

Primary Outcomes (1)

  • 25-Hydroxyvitamin D Concentration

    Circulating total 25(OH)D concentration measured in serum at visit 7, one month prior to delivery

    7 months

Study Arms (3)

cholecalciferol-400 IU

ACTIVE COMPARATOR

Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day

Drug: cholecalciferol (vitamin D3)Drug: cholecalciferol

cholecalciferol 2000 IU

EXPERIMENTAL

Experimental group receiving 2000 IU total vitamin D3/day.

Drug: cholecalciferol (vitamin D3)Drug: cholecalciferol

cholecalciferol 4000 IU

EXPERIMENTAL

Experimental group receiving 4000 IU/day cholecalciferol

Drug: cholecalciferol (vitamin D3)Drug: cholecalciferol

Interventions

randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day

cholecalciferol 2000 IUcholecalciferol 4000 IUcholecalciferol-400 IU

comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy

Also known as: vitamin D3
cholecalciferol 2000 IUcholecalciferol 4000 IUcholecalciferol-400 IU

Eligibility Criteria

Age16 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Women who are within the ages of 16-45 years
  • In good general health
  • Less than 12 weeks pregnant (based on last menstrual period)

You may not qualify if:

  • Mothers with preexisting type I or type II diabetes
  • Mothers with preexisting hypertension
  • Mothers with preexisting parathyroid disease or uncontrolled thyroid disease
  • Mothers with multiple fetuses (e.g., twins, triplets, etc.)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

Related Publications (6)

  • Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005 Feb;135(2):317-22. doi: 10.1093/jn/135.2.317.

    PMID: 15671234BACKGROUND
  • Hollis BW, Wagner CL. Normal serum vitamin D levels. N Engl J Med. 2005 Feb 3;352(5):515-6; author reply 515-6. doi: 10.1056/NEJM200502033520521. No abstract available.

    PMID: 15689596BACKGROUND
  • Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res. 2011 Oct;26(10):2341-57. doi: 10.1002/jbmr.463. Erratum In: J Bone Miner Res. 2011 Dec; 26(12):3001.

  • Hollis BW, Wagner CL. Vitamin D requirements and supplementation during pregnancy. Curr Opin Endocrinol Diabetes Obes. 2011 Dec;18(6):371-5. doi: 10.1097/MED.0b013e32834b0040.

  • Palacios C, Kostiuk LL, Cuthbert A, Weeks J. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2024 Jul 30;7(7):CD008873. doi: 10.1002/14651858.CD008873.pub5.

  • Wei W, Shary JR, Garrett-Mayer E, Anderson B, Forestieri NE, Hollis BW, Wagner CL. Bone mineral density during pregnancy in women participating in a randomized controlled trial of vitamin D supplementation. Am J Clin Nutr. 2017 Dec;106(6):1422-1430. doi: 10.3945/ajcn.116.140459. Epub 2017 Oct 18.

MeSH Terms

Conditions

Vitamin D Deficiency

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Results Point of Contact

Title
Dr. Carol Wagner
Organization
Medical University of South Carolina

Study Officials

  • Bruce W. Hollis, Ph.D.

    Medical University of South Carolina

    PRINCIPAL INVESTIGATOR
  • Carol L. Wagner, M.D.

    Medical University of South Carolina

    PRINCIPAL INVESTIGATOR
  • Donna Johnson, M.D.

    Medical University of South Carolina

    STUDY DIRECTOR
  • Thomas C. Hulsey, Sc.D.

    Medical University of South Carolina

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Pediatrics

Study Record Dates

First Submitted

February 15, 2006

First Posted

February 16, 2006

Study Start

January 1, 2004

Primary Completion

January 1, 2010

Study Completion

January 1, 2010

Last Updated

September 19, 2016

Results First Posted

August 9, 2016

Record last verified: 2016-08

Locations